Q2 revenue came in at an all-time high of NOK 16.6m (up 2% from Q1/20). Sales were driven by record high Cystatin C sales of NOK 8.5m, while fCAL was impacted by Covid-19 and ended at NOK 3.9m (- 26% from Q1/20). Fluctuations in sales revenue between quarters are to be expected. GCAL and fPELA should secure higher revenue growth over the next year. The clinical validation of the GCAL and the Covid-19 analysis development are factors to follow closely in 2020.
24 Aug 2020
Revenue growth continues and EBITA positive
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Revenue growth continues and EBITA positive
Q2 revenue came in at an all-time high of NOK 16.6m (up 2% from Q1/20). Sales were driven by record high Cystatin C sales of NOK 8.5m, while fCAL was impacted by Covid-19 and ended at NOK 3.9m (- 26% from Q1/20). Fluctuations in sales revenue between quarters are to be expected. GCAL and fPELA should secure higher revenue growth over the next year. The clinical validation of the GCAL and the Covid-19 analysis development are factors to follow closely in 2020.